跳转至内容
Merck
CN

MABC534

Anti-TPM3 Antibody, isoform TC22, clone TC22-4

clone TC22-4, from mouse

别名:

Tropomyosin alpha-3 chain, Gamma-tropomyosin, Tropomyosin-3, Tropomyosin-5, hTM5

登录 查看组织和合同定价。

选择尺寸

关于此项目

eCl@ss:
32160702
UNSPSC Code:
12352203

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

mouse

antibody form

purified antibody

antibody product type

primary antibodies

clone

TC22-4, monoclonal

species reactivity

human

technique(s)

ELISA: suitable, flow cytometry: suitable, immunohistochemistry: suitable, western blot: suitable

isotype

IgG1κ

NCBI accession no.

NP_000357

UniProt accession no.

P06753-4

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... TPM3(7170)

General description

Tropomyosins are dimmers of coiled-coil proteins that provide stability to actin filaments and regulate access of other actin-binding proteins. The human TPM3 gene (Gene ID 7170; also known as TM3, TM5, TRK, CFTD, NEM1, TM-5, TM30, CAPM1, TM30nm, TPMsk3, hscp30, HEL-189, HEL-S-82p, OK/SW-cl.5) encodes seven tropomyosin alpha-3 chain isoforms (UniProt P06753; also known as Tropomyosin-3) as a result of alternative splicing. Spliced variants 1, 2, 4, and 5 are also known as the skeletal muscle, TM30nm, TC22, and hTM5 isoform, respectively. The TC22 and the hTM5 variants are identical in sequence other than the 25 amino acids at their C-terminal end. TC22 is expressed in 100% of colorectal carcinomas, but is not expressed in normal colon epithelial cells. The anticarcinogenic potency of sulfasalazine (SASP) and its active metabolite 5-aminosalicylate (5-ASA, mesalamine) in protecting ulcerative colitis (UC) patients from developing colorectal cancer is directly linked to their efficacy in reducing cellular expression of TC22. Likewise, siRNA-mediated TC22 downregulation is shown to significantly alter several critical carcinogenic pathways in the human colon adenocarcinoma LS180 cells.
~32 kDa observed. Uncharacterized band(s) may appear in some lysates.

Immunogen

Recombinant human TC22 and boosts with TC22-specific C-terminal peptide.

Application

This Anti-TPM3 Antibody, isoform TC22, clone TC22-4 is validated for use in Western blotting, Immunohistochemistry, ELISA and FLow Cytometry for the detection of TPM3.
Western Blotting Analysis: A representative lot detected endogenous TC22 in human colorectal carcinoma T84 cell lysate, as well as recombinant human TC22, but not five other human TPM3 isoforms (Lin, J.L., et al. (2002). Gastroenterology. 123(1):152-162; Das, K.K., et al. (2009). Mol Pharmacol. 76(1):183-191).
ELISA Analysis: A representative lot specifically detected recombinant human TC22, but not five other human TPM3 isoforms (Das, K.K., et al. (2009). Mol Pharmacol. 76(1):183-191.).
Flow Cytometry Analysis: A representative lot detected time-dependent TC22 downregulation in LS180 cells upon 2 mM 5-Aminosalicylate (5-ASA) treatment (Das, K.K., et al. (2009). Mol Pharmacol. 76(1):183-191.)
Immunohistochemistry: Representative lots detected TC22 expression in human colon carcinoma and adenomatous polyp tissues, but not in normal colon tissue samples (Lin, J.L., et al. (2002). Gastroenterology. 123(1):152-162; Watari, J., et al. (2008). Clin Gastroenterol Hepatol. 6(4):409-17).

Biochem/physiol Actions

Clone TC22-4 selectively detects human tropomyosin alpha-3 chain (TMP3) spliced variant TC22 (isoform 4), but not spliced Isoform 1 (Skeletal muscle), 2 (TM30nm), 3, 5 (hTM5), 6, or 7.

Physical form

Format: Purified

Analysis Note

Evaluated by Western Blotting in recombinant human TC22 protein.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected TPM3 in 10 µg of recombinant human TC22 protein.

Other Notes

Concentration: Please refer to lot specific datasheet.

未找到合适的产品？  

试试我们的产品选型工具.

存储类别

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

White Paper: Further considerations of antibody validation and usage.
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System

A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor α (ERα) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERα is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERα is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERα for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持